Skip to content

Pupillography as Screening Tool for Brain Insulin Resistance

Pupillographie Als Screeningtest für Cerebrale Insulinresistenz

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03651661
Enrollment
22
Registered
2018-08-29
Start date
2018-07-03
Completion date
2019-01-07
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Cerebral insulin action is important in the regulation of whole body glucose metabolism. However, the cerebral insulin action differs between individuals - there is a so called cerebral insulin resistance. The influence of central insulin action on peripheral metabolism seems at least partially mediated via the autonomous nervous system. A noninvasive method to measure autonomic function is the pupillography. The aim of the study is to find out whether pupillography can be used to assess central insulin activity. Thus, pupillography will be performed in 30 normal weight and 30 overweight subjects before and after application insulin intranasally.

Interventions

DIAGNOSTIC_TESTPupillography

Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.

DRUGhuman insulin

human insulin administered as nasal spray

DRUGplacebo

placebo administered as nasal spray

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* voluntary adults * HbA1c \<5.8% * Age between 18 and 60 years * written consent

Exclusion criteria

* There is a pregnancy or pregnancy can not be excluded * lactating women * Minors or non-consenting subjects are also excluded * Acute illness or infection within the last 4 weeks * Neurological and psychiatric disorders * intake of centrally acting drugs * Subjects with hemoglobin levels Hb \<12g / dl (in females), Hb \<14g / dl (males) * Allergic diseases against one of the substances used

Design outcomes

Primary

MeasureTime frameDescription
Measurements of autonomic nervous system activity by pupillographyMeasurements baseline and change to baseline 15 minutes and 30 minutes after spray applicationThere will be measurements of autonomic nervous system activity by pupillography in order to identify central insulin action. The primary variable is the pupil width change in pupillography before compared to after intranasal insulin/placebo administration in 30 lean subjects. The investigation takes place in a darkened room with low backlight of about 5-10lx. The pupillographic recording is carried out with a commercially available device, F2D2 (Amtech Germany). In this case, the pupil width is recorded for 6 minutes continuously before and after nasal insulin (also 16 strokes of 10 E) or placebo doses with an infrared camera permanently mounted in a video goggle. Additionally, a possible change of the pupillary light reflection to monochromatic light is measured. Evaluation parameters are latency, amplitude and re-dilatation behavior.
Measurements of latency of pupil response to light stimulation.Measurements baseline and change to baseline 15 minutes and 30 minutes after spray applicationThere will be measurements of autonomic nervous system activity by pupillography in order to identify central insulin action. The investigation takes place in a darkened room with low backlight of about 5-10lx. The pupillographic recording is carried out with a commercially available device, F2D2 (Amtech Germany). A possible change of the pupillary light reflection to monochromatic light is measured. Evaluation parameter is latency. The responses before and after nasal spray administration will be compared.
Measurements of amplitude of pupil response to light stimulation.Measurements baseline and change to baseline 15 minutes and 30 minutes after spray applicationThere will be measurements of autonomic nervous system activity by pupillography in order to identify central insulin action. The investigation takes place in a darkened room with low backlight of about 5-10lx. The pupillographic recording is carried out with a commercially available device, F2D2 (Amtech Germany). A possible change of the pupillary light reflection to monochromatic light is measured. Evaluation parameter is amplitude . The responses before and after nasal spray administration will be compared.
Measurements of re-dilation behaviour of pupil response to light stimulation.Measurements baseline and change to baseline 15 minutes and 30 minutes after spray applicationThere will be measurements of autonomic nervous system activity by pupillography in order to identify central insulin action. The investigation takes place in a darkened room with low backlight of about 5-10lx. The pupillographic recording is carried out with a commercially available device, F2D2 (Amtech Germany). A possible change of the pupillary light reflection to monochromatic light is measured. Evaluation parameter is re-dilatation behavior. The responses before and after nasal spray administration will be compared.

Secondary

MeasureTime frameDescription
Autonomic nervous systemMeasurements baseline and change to baseline 15 minutes and 30 minutes after spray applicationeffect of nasal insulin or placebo spray on autonomic nervous system tone measured by heart rate variability.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026